stockrowXeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
Follow XERS
Alert me
Xeris Biopharma Holdings, Inc. (XERS) Revenue growth
Xeris Biopharma Holdings, Inc.'s revenue growth over the twelve months to 30 September 2026 was 38.4%, down 5.4 percentage points from fiscal 2025 (43.7%). Over the past ten years it has ranged from −30.9% (fiscal 2016) to 650.7% (fiscal 2020); the current reading is higher than 40% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 5.22% and above the Healthcare sector median of 7.98%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 43.7% | 19.83 |
| FY2024 | 23.9% | (24.79) |
| FY2023 | 48.7% | (73.64) |
| FY2022 | 122.3% | (20.35) |
| FY2021 | 142.7% | (508.06) |
| FY2020 | 650.7% | 638.39 |
| FY2019 | 12.3% | (43.38) |
| FY2018 | 55.7% | 10.98 |
| FY2017 | 44.7% | 75.65 |
| FY2016 | −30.9% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 44.2% | 15.42 |
| Jun 2026 | 28.7% | (9.53) |
| Mar 2026 | 38.3% | (4.51) |
| Dec 2025 | 42.8% | 5.72 |
| 33 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| ALVO Alvotech compare | 364.3% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 245.2% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 60.3% |
| XERS Xeris Biopharma Holdings, Inc. | 38.4% |
| PBH Prestige Consumer Healthcare Inc. compare | 5.10% |
| PRGO Perrigo Company plc compare | −4.47% |
| TRLV Trulieve Cannabis Corp. compare | −9.09% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −77.1% |
| RGC Regencell Bioscience Holdings Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.98% |
| Market median | 7.71% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on XERS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement